T he optimal treatment duration of aspirin and a P2Y 12 receptor antagonist after percutaneous coronary intervention (PCI) has vexed cardiologists since the introduction of drug-eluting stents (DES) approximately a decade ago. A short (2-to 4-week) course of aspirin and a thienopyridine after elective implantation of a bare-metal stent became the standard of care by default from randomized trials that observed subjects for only a short period after PCI (1, 2) , not from studies that compared different treatment durations. An ongoing hazard of late stent thrombosis was observed when thienopyridine therapy was withdrawn beyond 3 to 6 months after implantation of first-generation DES (3), and histopathological studies linked these events to the presence of inflammation, delayed endothelialization, and neoatherosclerosis (4, 5) . The current consensus, codified by the American College of Cardiology Foundation/American Heart Association/ Society for Cardiovascular Angiography and Interventions PCI guidelines, is to treat DES patients with at least 12 months of dual antiplatelet therapy (DAPT), unless the risk of morbidity from bleeding outweighs the anticipated benefit afforded by continued P2Y 12 inhibitor therapy (6) . From a philosophical perspective, the unnerving experience with first-generation DES shifted the priorities of the interventional cardiologist at the time of discharge from treating the patient to treating the stent.
The second-generation DES are associated with better endothelial healing, likely due to differences in strut design, polymer quantity and composition, use of rapamycin analogues, and drug-release kinetics matthew@scrippshealth.org.
